These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 24747602)

  • 1. MicroRNAs as prognostic markers in ovarian cancer.
    Llauradó M; Majem B; Altadill T; Lanau L; Castellví J; Sánchez-Iglesias JL; Cabrera S; De la Torre J; Díaz-Feijoo B; Pérez-Benavente A; Colás E; Olivan M; Doll A; Alameda F; Matias-Guiu X; Moreno-Bueno G; Carey MS; Del Campo JM; Gil-Moreno A; Reventós J; Rigau M
    Mol Cell Endocrinol; 2014 Jun; 390(1-2):73-84. PubMed ID: 24747602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs in Ovarian Cancer.
    Katz B; Tropé CG; Reich R; Davidson B
    Hum Pathol; 2015 Sep; 46(9):1245-56. PubMed ID: 26216350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.
    Mezzanzanica D; Bagnoli M; De Cecco L; Valeri B; Canevari S
    Int J Biochem Cell Biol; 2010 Aug; 42(8):1262-72. PubMed ID: 20035894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
    Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
    Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs in ovarian cancer biology and therapy resistance.
    van Jaarsveld MT; Helleman J; Berns EM; Wiemer EA
    Int J Biochem Cell Biol; 2010 Aug; 42(8):1282-90. PubMed ID: 20083225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
    Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
    Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
    Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status on microRNAs as biomarkers for ovarian cancer.
    Prahm KP; Novotny GW; Høgdall C; Høgdall E
    APMIS; 2016 May; 124(5):337-55. PubMed ID: 26809719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNAs in malignant melanoma.
    Völler D; Ott C; Bosserhoff A
    Clin Biochem; 2013 Jul; 46(10-11):909-17. PubMed ID: 23360785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of microRNAs in melanoma.
    Luo C; Weber CE; Osen W; Bosserhoff AK; Eichmüller SB
    Eur J Cell Biol; 2014; 93(1-2):11-22. PubMed ID: 24602414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical and diagnostic role of microRNAs in ovarian carcinoma.
    Davidson B; Tropé CG; Reich R
    Gynecol Oncol; 2014 Jun; 133(3):640-6. PubMed ID: 24713546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miRNAs as molecular biomarkers of cancer.
    Fabbri M
    Expert Rev Mol Diagn; 2010 May; 10(4):435-44. PubMed ID: 20465498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
    Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
    Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-analytical variables in miRNA analysis.
    Becker N; Lockwood CM
    Clin Biochem; 2013 Jul; 46(10-11):861-8. PubMed ID: 23466658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of microRNAs in colorectal cancer.
    Liu M; Chen H
    J Genet Genomics; 2010 Jun; 37(6):347-58. PubMed ID: 20621017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetically regulated microRNAs and their prospect in cancer diagnosis.
    Kita Y; Vincent K; Natsugoe S; Berindan-Neagoe I; Calin GA
    Expert Rev Mol Diagn; 2014 Jul; 14(6):673-83. PubMed ID: 24914586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression.
    Faggad A; Budczies J; Tchernitsa O; Darb-Esfahani S; Sehouli J; Müller BM; Wirtz R; Chekerov R; Weichert W; Sinn B; Mucha C; Elwali NE; Schäfer R; Dietel M; Denkert C
    J Pathol; 2010 Feb; 220(3):382-91. PubMed ID: 19960504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetics in ovarian cancer.
    Seeber LM; van Diest PJ
    Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miRNA control of apoptotic programs: focus on ovarian cancer.
    Mezzanzanica D; Canevari S; Cecco LD; Bagnoli M
    Expert Rev Mol Diagn; 2011 Apr; 11(3):277-86. PubMed ID: 21463237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.
    Yang L; Li N; Wang H; Jia X; Wang X; Luo J
    Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.